Please use this identifier to cite or link to this item:
Title: Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
Author: Montes Moreno, Santiago
Batlle, Ana
González de Villambrosía, Sonia
Sánchez-Espiridión, Beatriz
Cereceda, Laura
González Barca, Eva
Purroy, Noelia
Pardal, Emilia
Martín, Alejandro
Grande, Carlos
Mazorra, Francisco
Insunza, Andrés
Quero, Cristina
Aguiar, David
Cruz, Miguel Ángel
Rueda Dominguez, Antonio
Llanos, Marta
Gómez Codina, Jose
García Arroyo, Francisco Ramón
Caballero, Dolores
Conde, Eulogio
López, Andres
Provencio, Mariano
Piris, Miguel A.
Keywords: Quimioteràpia
Cèl·lules B
Cèl·lules mare
B cells
Stem cells
Issue Date: 1-Aug-2014
Publisher: Ferrata Storti Foundation
Abstract: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.
Note: Reproducció del document publicat a:
It is part of: Haematologica, 2014, vol. 99, num. 8, p. 138-141
Related resource:
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
679858.pdf196.73 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.